Biofrontera Inc. Reports 17.4% Revenue Growth to $10.1 Million in Q1 2026

Biofrontera Inc. reported its financial results for the first quarter of 2026, revealing a net product revenue of $10.1 million, a 17.4% increase from $8.6 million in the same period last year. This growth was primarily driven by a 15.9% rise in unit sales of its flagship product, Ameluz, alongside the impact of a price increase implemented in late 2025. Despite the revenue increase, the company recorded a net loss of $4.8 million, slightly higher than the $4.2 million loss reported in the first quarter of 2025. The loss per share improved to $(0.41) from $(0.47) year-over-year, reflecting a higher average number of shares outstanding due to recent equity issuances.

Operating expenses for the quarter totaled $14.4 million, up from $13.1 million in the prior year, largely due to increased selling, general, and administrative expenses, which rose by 27.1% to $11.0 million. This increase was attributed to heightened sales activities and legal costs associated with ongoing patent-related claims. Notably, the cost of revenues from related parties decreased significantly by 40.5% to $1.8 million, a result of the transition to a new cost structure following the Strategic Transaction with Biofrontera AG, which has allowed for a more favorable pricing model for Ameluz.

In terms of operational metrics, Biofrontera's cash and cash equivalents stood at $6.3 million as of March 31, 2026, a slight decrease from $6.4 million at the end of 2025. The company reported a net cash outflow from operations of $0.1 million, a significant improvement compared to the $4.1 million outflow in the same quarter of the previous year. The reduction in cash used in operations was primarily due to improved collections on accounts receivable, reflecting the seasonal nature of its product sales.

Strategically, Biofrontera has focused on expanding its market presence in the United States, particularly through the commercialization of Ameluz and the RhodoLED Lamps. The company has also taken control of all clinical trials related to Ameluz in the U.S. as of June 2024, which is expected to enhance its operational efficiency. However, the company faces challenges, including a recent ruling from the International Trade Commission that could impact its ability to sell certain products in the U.S. market.

Looking ahead, Biofrontera aims to continue its growth trajectory by expanding its customer base and enhancing product adoption. The company is also exploring additional financing options to support its operations and mitigate liquidity concerns, as it has raised doubts about its ability to sustain operations over the next twelve months without securing further capital. The management remains optimistic about achieving profitability through strategic initiatives and operational improvements.